Matthew P Deek

[Shankar Siva @_ShankarSiva]

@PBlanchardMD discusses SABR in oligometastatic #prostatecancer #pcsm - in both hormone sensitive and castrate resistant patients… and reminds us that lung metastases have a similar prognosis to bone secondaries; and the HR of benefit is the same in all studies ~0.50 #SABR2025

[Zohaib Sherwani, MD @zohaib_sherwani]

Our amazing @RutgersCancer M3 @anna_2santos received the Medical Student Fellowship award at as an M2 and presented her work on Genetic Biomarkers of Radiation sensitivity at @ASTRO_org this year. She was mentored by our own @SalmaJabbour1 and @matthewdeek

She then de-stressed with the pups at paw zone🥳🥹 Proud of you Anna!

@BHaffty

[UroToday.com @urotoday]

Phase 2 Randomized High-risK metachroNous oligometastatIc #ProstateCancer with hiGh-Risk Mutations Treated with Metastasis Directed Therapy and Niraparib/abiraterone Acetate + Prednisone - The #KNIGHTS trial.

The phase 2 KNIGHTS trial is testing MDT + niraparib/abiraterone in high-risk metachronous oligometastatic #PCa with HiRi mutations.
Could this intensification strategy improve outcomes?

Presentation by @matthewdeek @RWJMS. #GU25 written coverage by @RKSayyid @USC > https://t.co/CJk0vk1Uxb @ASCO

[AACR @AACR]

AI in Radiation Therapy:
@SteveJiangPhD, @matthewdeek, Danielle S. Bitterman, Philip A. Sutera, and Ruijiang Li addressed this topic in a plenary session at the AACR Conference on Translating Targeted Therapies in Combination with Radiotherapy. #AACRradiation25 @dbittermanmd

[UroToday.com @urotoday]

This multi-institutional study highlights the benefits of combining MDT with ADT for oligometastatic castration-sensitive #ProstateCancer. Findings suggest improved progression-free survival with combined treatment vs MDT alone. #AuthorCommentary from @matthewdeek, Philip Sutera, and @ChrisSweens1 on UroToday > https://t.co/pSgmBB1q20 @EurUrolOncol

[UroToday.com @urotoday]

This multi-institutional study highlights the benefits of combining MDT with ADT for oligometastatic castration-sensitive #ProstateCancer. Findings suggest improved progression-free survival with combined treatment vs MDT alone. #AuthorCommentary from @matthewdeek, Philip Sutera, and @ChrisSweens1 on UroToday > https://t.co/pSgmBB1q20 @EurUrolOncol

[Matthew P Deek @matthewdeek]

@piet_ost @CTuscanoMD @ZilliThomas @ChadTangMD @_ShankarSiva @PBlanchardMD @PaulSargos @urotoday Yes new data soon!

[PDBrown @PDBrownOnc]

@ErinGillespieMD @Rrkotecha @simonpowell213 @CJTsaiMDPhD @JYangMDPhD Excellent editorial @matthewdeek Dr. Tran & @SalmaJabbour1
Eval for Met Directed Tx:
•Oligo Mets
•Oligo Prog Dz
•Proph High Risk Dz
•Symptomatic Dz

https://t.co/fAPBSUE8i2

[Rutgers Radiation Oncology Residency Program @RU_RadOnc]

Congratulations to @RU_RadOnc faculty, Dr. Deek @matthewdeek and chief resident, Dr. Kim @JKimMDPhD for being recognized by @ASTRO_org for their contributions to the advancement of our field. @RutgersCancer @RWJMS @Rutgers_NJMS @RWJBarnabas

[Matthew P Deek @matthewdeek]

@DrHaigentz @RU_RadOnc @BHaffty I had a little help :)

[Matthew P Deek @matthewdeek]

@sophia_kamran @PCF_Science @HenningWillers @TylerSbrt @aadel_chaudhuri @julian_hong @soulehoward1 @charlesryanmd @AndreaMiyahira @rweichselbaum Thank you for organizing. Great sessions!

[UroToday.com @urotoday]

Multi-institutional analysis of metastasis directed therapy with or without ADT in oligometastatic castration-sensitive #ProstateCancer. Presented by @matthewdeek @RWJBarnabas. #AUA23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/QIeDbyDEiT @AmerUrological

[Matthew P Deek @matthewdeek]

@PDBrownOnc Very important trial for our patients !

[Matthew P Deek @matthewdeek]

@HenningWillers @OncoAlert @ASTRO_org @subatomicdoc @mouwlab @sophia_kamran @aadel_chaudhuri @DrLesterColl @NicholasZaorsky Thank you!

[Rutgers Radiation Oncology Residency Program @RU_RadOnc]

Please come and join our faculty @matthewdeek presenting his study on oligometasis #ASTRO2022 @ASTRO_org @RU_RadOnc @RutgersCancer @RWJMS @Rutgers_NJMS

[Rachel Glicksman @r_glicksman]

SBRT for oligometastasis: GUst do it? Check out our oncology scan in @IJROBP with oligomet experts @aleberlin2 @drdavidpalma @matthewdeek @CJTsaiMDPhD @_ShankarSiva @piet_ost https://t.co/3Xb4CroGZo . Thank you @aleberlin2 @sueyom @IJROBP for the opportunity!

[Journal of Clinical Oncology @JCO_ASCO]

🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observation in oligometastatic #ProstateCancer
🎯 Largest benefit for patients harboring a high-risk mutation #PCSM @matthewdeek @piet_ost https://t.co/OO8kcTVvFT

[Matthew P Deek @matthewdeek]

@birensaraiya @RutgersCancer Thank you!